A comparison of physiochemical property profiles of development and marketed oral drugs

Journal of Medicinal Chemistry

Volumn 46, Issue 7, 2003, Pages 1250-1256

  Wenlock, Mark C ^a   Austin, Rupert P ^a   Barton, Patrick ^a   Davis, Andrew M ^a   Leeson, Paul D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PRAMIPEXOLE;

ARTICLE; CHEMICAL BOND; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; HUMAN; LIPOPHILICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY;

ADMINISTRATION, ORAL; CHEMISTRY, PHYSICAL; DATABASES, FACTUAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HYDROGEN BONDING; MARKETING; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 0037468884     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021053p     Document Type: Article

References (27)

1. Prentis, R. A.; Lis, Y.; Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharm. 1988, 25, 387-396.
2. Venkatesh, S.; Lipper, R. A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 2000, 89, 145-154.
3. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today 1998, 1, 387-393.
4. van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001, 44, 1313-1333.
5. Riley, R. J.; Parker, A. J.; Trigg, S.; Manners, C. N. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm. Res. 2001, 18, 652-655.
6. Lewis, D. F. V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Towards the prediction of human P450 substrate specificity and metabolism. Biochem. Pharmacol. 2000, 60, 293-306.
7. Smith, D. A.; Ackland, M. J.; Jones, B. C. Properties of cytochrome P450 isoenzymes and their substrates part 2: Properties of cytochrome P450 substrates. Drug Discovery Today 1997, 2, 479-486.
8. Rowley, M.; Kulagowski, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J. A.; Foster, A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Tricklebank, M. D.; Leeson, P. D. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 1997, 40, 4053-4068.
9. Barton, P.; Davis, A. M.; McCarthy, D. J.; Webborn, P. J. H. Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients. J. Pharm. Sci. 1997, 86, 1034-1039.
10. Chan, O. H.; Stewart, B. H. Physiochemical and drug-delivery considerations for oral drug bioavailability. Drug Discovery Today 1996, 1, 461-473.
11. Palm, K.; Luthman, K.; Ungell, A.; Strandlund, G.; Artursson, P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 1996, 85, 32-39.
12. Smith, D. A.; Jones, B. C.; Walker, D. K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 1996, 16, 243-266.
13. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Raevsky, O. A. Estimation of Caco-2 cell permeability using calculated molecular descriptors. Quant. Struct.-Act. Relat. 1996, 15, 480-490.
14. Lázníček, M.; Lázníčková, A. The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. J. Pharm. Biomed. Anal. 1995, 13, 823-828.
15. Austin, R. P.; Davis, A. M.; Manners, C. N. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J. Pharm. Sci. 1995, 84, 1180-1183.
16. Pidgeon, C.; Ong, S.; Liu, H.; Qiu, X.; Pidgeon, M.; Dantzig, A. H.; Munroe, J.; Hornback, W. J.; Kasher, J. S.; Glunz, L.; Szczerba, T. IAM chromatography: An in vitro screen for predicting drug membrane permeability. J. Med. Chem. 1995, 38, 590-594.
17. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeny, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
18. Sakaeda, T.; Okamura, N.; Nagata, S.; Yagami, T.; Horinouchi, M.; Okumura, K.; Yamashita, F.; Hashida, M. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol. Pharm. Bull. 2001, 24, 935-940.
19. Adis International Ltd.
20. Physicians Desk Reference, 53rd ed.; Medical Economics Company: Montvale, USA, 1999.
21. Advanced Chemistry Development Inc., Toronto, Canada.
22. Accelrys Inc., San Diego, California, USA.
23. Daniel, W. W. Applied Nonparametric Statistics, 2nd ed.; Payne, M., Ed.; PWS-KENT Publishing Company: Boston, USA, 1990; pp 90-95.
24. Veber, D. F.; Johnson, S. R.; Cheng, H.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
25. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
26. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem. 1999, 111, 3962-3967; Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748.
27. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem. 1999, 111, 3962-3967; Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748.